NCT03697655 - Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma | Biotech Hunter

Enrollment

274

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

September 30, 2020

Study Completion Date

July 31, 2024

Conditions

Multiple Myeloma

Interventions

DRUG

Daratumumab 20 MG/ML [Darzalex]

Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks

Trial Locations (2)

60-569

RECRUITING

Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu; Oddział Hematologii i Transplantacji Szpiku, Poznan

02-776

RECRUITING

Instytut Hematologii i Transfuzjologii, Warsaw